AT2 receptor‐mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR
Open accessThe DOI matches its Crossref record.
Abstract
In the present study, we investigated the role of the angiotensin II type 2 receptor (AT 2) receptor in the regulation of regional haemodynamics in spontaneously hypertensive rats (SHR). We tested the hypothesis that AT 2 receptor activation directly causes vasodilatation. Mean arterial pressure (MAP), renal, mesenteric and hindquarters flows and conductances were measured in various groups of conscious rats that received the following drug combinations on separate days: the AT 1 receptor antagonist, candesartan (5 or 10 μ g kg−1 i.v.) alone, the AT 2 receptor agonist, CGP42112 (1 μ g kg−1 min−1) alone and candesartan plus CGP42112. Low‐dose candesartan (5 μ g kg−1) caused renal vasodilatation, while CGP 42112 alone caused minimal haemodynamic effects. In the presence of candesartan, CGP42112 caused a marked depressor effect together with generalised vasodilatation that was abolished by the coinfusion of the AT 2 receptor antagonist, PD123319 (50 μ g kg−1 min−1), with the candesartan and CGP42112 combination. PD123319, given alone, increased MAP and reduced renal and mesenteric conductances. We also confirmed that the enhanced vasodilatation evoked by candesartan plus CGP42112 was not due to additional AT 1 receptor blockade, since angiotensin II‐mediated vasoconstriction was inhibited by a similar magnitude in the combination treatment compared with candesartan alone. Analogous experiments in Wistar–Kyoto rats did not demonstrate significantly enhanced effects due to candesartan plus CGP42112. Collectively, these data suggest that, in SHR, AT 2 receptors tonically modulate vascular tone and that direct AT 2 receptor‐mediated vasodilatation was unmasked by AT 1 receptor blockade. British Journal of Pharmacology (2004) 142, 821–830. doi:10.1038/sj.bjp.0705838
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Counter-regulatory renin–angiotensin system in cardiovascular disease
Paz Ocaranza, M., Riquelme, J. A., García, L., Jalil, J. E., Chiong, M., Santos, R. A. S., & Lavandero, S. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0244-8 · Cited by 561
Li, X. C., Zhang, J., & Zhuo, J. L. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.06.005 · Cited by 435
Self-citationThe Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target
Steckelings, U. M., Widdop, R. E., Sturrock, E. D., Lubbe, L., Hussain, T., Kaschina, E., Unger, T., Hallberg, A., Carey, R. M., & Sumners, C. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000281 · Cited by 97
Self-citationSampson, A. K., Hilliard, L. M., Moritz, K. M., Thomas, M. C., Tikellis, C., Widdop, R. E., & Denton, K. M. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00256.2011 · Cited by 75
“It is now clear that angiotensin-converting enzyme 2 (ACE2) cleaves ANG II to form ANG (1–7) (38, 39), a peptide that acts via the Mas receptor (masR) but has also been reported to act via the type 2 angiotensin II receptor (AT2R), resulting in vasodilation and antiproliferation (19, 27, 40).”
BackgroundSelf-citationChen, H., Peng, J., Wang, T., Wen, J., Chen, S., Huang, Y., & Zhang, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115370 · Cited by 19
Metadata
- Authors
- Li, X. C., & Widdop, R. E.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2004-07
- Volume
- 142
- Issue
- 5
- Pages
- 821-830
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2053827513
- Cited by
- 82
- References
- 0
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AT2 receptor‐mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. https://app.cochat.ai/papers/10.1038/sj.bjp.0705838
- The paper
- Li, X. C., & Widdop, R. E. (2004). AT2 receptor‐mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0705838
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.